Novartis Obtains Japanese Price Listing For Ilaris After Brief Delay
This article was originally published in PharmAsia News
Executive Summary
Japan’s Social Central Medical Insurance Agency (Chuikyo) approved the price listing for Novartis AG's Ilaris (canakinumab) for rare inflammation, cryopyrin-associated periodic syndrome Nov. 18.